|Speaker:||Brian Campion, Ph.D.|
|Title:||VP Corporate Development|
|Primary Industry:||Pharma & Biotech|
|Executive Summary:||SpeciGen employs protein cage nanotechnology for drug delivery, initially focused on making approved chemotherapeutic drugs safer and more effective. In 2007, the company will perform pre-clinical studies in animal models of disease to prove safety and efficacy prior to proceeding to human clinical trials.
In preliminary in vitro and in vivo studies, the company has shown the ability to sequester chemotherapeutic drugs inside protein cages that are targeted to cancer cells by peptides attached to the outside of the cages. A variety of methods to release the drug have been employed. The goal of targeted and controlled drug delivery and release is lowered toxicity and increased efficacy in a variety of refractory, life-threatening cancers (breast, lung and colorectal).
SpeciGen\'s technology is being developed in research collaborations with Montana State University, the NIH, Stanford School of Medicine, the Burnham Institute and Calvert Research Institute. The focus of these collaborations include diagnostic imaging and therapy of cancer, cardiovascualr and infectious diseases.
The company is seeking investors to participate in a Series A Preferred Stock offering to help fund the developmental studies leading to human clinical trials. Inquiries about licensing product candidates are invited.|